Stöckle E, Chauvergne J, Pigneux J, Avril A, Bussières E, Thomas L, Chevalier M, Marée D
Service de chirurgie, fondation Bergonié, Bordeaux, France.
Bull Cancer. 1990;77(11):1087-98.
A series of thirty consecutive epithelial ovarian cancer patients were reviewed after long-term follow-up (more than 5 y) since their second-look operation (SLO). All patients had advanced tumors (stages IIb-IV). Primary chemotherapy consisted of a cisplatin-associated regimen. For all patients adjuvant treatment had been planned after completion of the SLO. Mean follow-up after SLO was 68 months (47-103 months). Tumor status at SLO divided the patients in 2 subgroups: Group A = 13 patients (43%), with no evidence of histologically proved disease at time of operation (NED); Group B = 17 patients (57%), with macroscopic persistence of tumor. Survival was significantly better in the first group than in the second (77% at 5 yr vs less than 25%). Recurrence rate in the NED group was 7.7% (1 recurrence at 32 months). Eight of 17 patients with gross tumor at SLO underwent satisfactory resection. However, recurrence rate was high (75%) and survival rate was low (25% at 5 yrs). This result was not significantly better than that of patients with no optimal resection at SLO (9 patients, survival 22%). Second effort resection at SLO does not seem to be beneficial in these patients after partial failure of initial chemotherapy with cisplatin. The usefulness of systematic second look operations is discussed. Controlled randomized trials should be made to determine the exact role of SLO in ovarian cancer treatment.
对30例连续的上皮性卵巢癌患者进行了回顾性研究,这些患者自二次探查手术(SLO)后接受了长期随访(超过5年)。所有患者均为晚期肿瘤(IIb-IV期)。初始化疗采用顺铂联合方案。所有患者在SLO完成后均计划接受辅助治疗。SLO后的平均随访时间为68个月(47-103个月)。根据SLO时的肿瘤状态将患者分为2个亚组:A组=13例患者(43%),手术时无组织学证实的疾病证据(NED);B组=17例患者(57%),肿瘤有肉眼可见的残留。第一组的生存率明显高于第二组(5年时为77% vs 低于25%)。NED组的复发率为7.7%(32个月时1例复发)。17例SLO时有大体肿瘤的患者中有8例接受了满意的切除。然而,复发率很高(75%),生存率很低(5年时为25%)。这一结果并不明显优于SLO时未进行最佳切除的患者(9例,生存率22%)。在初始顺铂化疗部分失败后,SLO时的二次努力切除对这些患者似乎并无益处。讨论了系统性二次探查手术的实用性。应进行对照随机试验以确定SLO在卵巢癌治疗中的确切作用。